These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27428433)

  • 41. Multiple components of the nuclear pore complex interact with the amino-terminus of MX2 to facilitate HIV-1 restriction.
    Dicks MDJ; Betancor G; Jimenez-Guardeño JM; Pessel-Vivares L; Apolonia L; Goujon C; Malim MH
    PLoS Pathog; 2018 Nov; 14(11):e1007408. PubMed ID: 30496303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CryoEM structure of MxB reveals a novel oligomerization interface critical for HIV restriction.
    Alvarez FJD; He S; Perilla JR; Jang S; Schulten K; Engelman AN; Scheres SHW; Zhang P
    Sci Adv; 2017 Sep; 3(9):e1701264. PubMed ID: 28929138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Binding of host factors to stabilized HIV-1 capsid tubes.
    Selyutina A; Bulnes-Ramos A; Diaz-Griffero F
    Virology; 2018 Oct; 523():1-5. PubMed ID: 30056211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Capsid proteins of enveloped viruses as antiviral drug targets.
    Klumpp K; Crépin T
    Curr Opin Virol; 2014 Apr; 5():63-71. PubMed ID: 24607800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Novel Phenotype Links HIV-1 Capsid Stability to cGAS-Mediated DNA Sensing.
    Siddiqui MA; Saito A; Halambage UD; Ferhadian D; Fischer DK; Francis AC; Melikyan GB; Ambrose Z; Aiken C; Yamashita M
    J Virol; 2019 Aug; 93(16):. PubMed ID: 31167922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon but not MxB inhibits foamy retroviruses.
    Bähr A; Singer A; Hain A; Vasudevan AA; Schilling M; Reh J; Riess M; Panitz S; Serrano V; Schweizer M; König R; Chanda S; Häussinger D; Kochs G; Lindemann D; Münk C
    Virology; 2016 Jan; 488():51-60. PubMed ID: 26609934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model.
    Yant SR; Mulato A; Hansen D; Tse WC; Niedziela-Majka A; Zhang JR; Stepan GJ; Jin D; Wong MH; Perreira JM; Singer E; Papalia GA; Hu EY; Zheng J; Lu B; Schroeder SD; Chou K; Ahmadyar S; Liclican A; Yu H; Novikov N; Paoli E; Gonik D; Ram RR; Hung M; McDougall WM; Brass AL; Sundquist WI; Cihlar T; Link JO
    Nat Med; 2019 Sep; 25(9):1377-1384. PubMed ID: 31501601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
    Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of the amino-terminal domain of Mx2/MxB-dependent interaction with the HIV-1 capsid.
    Kong J; Xu B; Wei W; Wang X; Xie W; Yu XF
    Protein Cell; 2014 Dec; 5(12):954-7. PubMed ID: 25363729
    [No Abstract]   [Full Text] [Related]  

  • 51. MX2-mediated innate immunity against HIV-1 is regulated by serine phosphorylation.
    Betancor G; Jimenez-Guardeño JM; Lynham S; Antrobus R; Khan H; Sobala A; Dicks MDJ; Malim MH
    Nat Microbiol; 2021 Aug; 6(8):1031-1042. PubMed ID: 34282309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Different Nuclear Localization Signals on the Subcellular Localization and Anti-HIV-1 Function of the MxB Protein.
    Chai K; Wang Z; Pan Q; Tan J; Qiao W; Liang C
    Front Microbiol; 2021; 12():675201. PubMed ID: 34093497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mx GTPases: dynamin-like antiviral machines of innate immunity.
    Haller O; Staeheli P; Schwemmle M; Kochs G
    Trends Microbiol; 2015 Mar; 23(3):154-63. PubMed ID: 25572883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trend of drug-resistant HIV type 1 emergence among therapy-naive patients in Nagoya, Japan: an 8-year surveillance from 1999 to 2006.
    Ibe S; Hattori J; Fujisaki S; Shigemi U; Fujisaki S; Shimizu K; Nakamura K; Kazumi T; Yokomaku Y; Mamiya N; Hamaguchi M; Kaneda T
    AIDS Res Hum Retroviruses; 2008 Jan; 24(1):7-14. PubMed ID: 18275342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan.
    Hattori J; Shiino T; Gatanaga H; Yoshida S; Watanabe D; Minami R; Sadamasu K; Kondo M; Mori H; Ueda M; Tateyama M; Ueda A; Kato S; Ito T; Oie M; Takata N; Hayashida T; Nagashima M; Matsuda M; Ibe S; Ota Y; Sasaki S; Ishigatsubo Y; Tanabe Y; Koga I; Kojima Y; Yamamoto M; Fujita J; Yokomaku Y; Koike T; Shirasaka T; Oka S; Sugiura W
    Antiviral Res; 2010 Oct; 88(1):72-9. PubMed ID: 20692295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolutionary pathways of transmitted drug-resistant HIV-1.
    Pingen M; Nijhuis M; de Bruijn JA; Boucher CA; Wensing AM
    J Antimicrob Chemother; 2011 Jul; 66(7):1467-80. PubMed ID: 21502281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
    Clementi M
    New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MX2 is an interferon-induced inhibitor of HIV-1 infection.
    Kane M; Yadav SS; Bitzegeio J; Kutluay SB; Zang T; Wilson SJ; Schoggins JW; Rice CM; Yamashita M; Hatziioannou T; Bieniasz PD
    Nature; 2013 Oct; 502(7472):563-6. PubMed ID: 24121441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
    Koval CE; Dykes C; Wang J; Demeter LM
    Virology; 2006 Sep; 353(1):184-92. PubMed ID: 16797050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.